Status:
TERMINATED
Safety & Efficacy of Eculizumab to Prevent AMR in Living Donor Kidney Transplant Recipients Requiring Desensitization
Lead Sponsor:
Alexion Pharmaceuticals, Inc.
Conditions:
Antibody Mediated Rejection
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
The purpose of this trial was to determine the safety and efficacy of eculizumab in the prevention of antibody-mediated rejection (AMR) in sensitized recipients of a living donor kidney transplant req...
Detailed Description
The main objective of this study was to evaluate the safety and efficacy of eculizumab to prevent AMR in sensitized recipients of living donor kidney transplants requiring desensitization therapy prio...
Eligibility Criteria
Inclusion
- Male or female patients ≥18 years old
- Patients with Stage IV or Stage V chronic kidney disease who will receive a kidney transplant from a living donor to whom they are sensitized and require desensitization prior to transplantation
Exclusion
- ABO incompatible with living donor
- Any medical condition that, in the opinion of the Investigator, might interfere with the patient's participation in the study, poses an added risk for the patient, or confounds the assessment of the patient
Key Trial Info
Start Date :
November 2 2011
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 13 2015
Estimated Enrollment :
102 Patients enrolled
Trial Details
Trial ID
NCT01399593
Start Date
November 2 2011
End Date
November 13 2015
Last Update
October 3 2017
Active Locations (41)
Enter a location and click search to find clinical trials sorted by distance.
1
Birmingham, Alabama, United States, 35294
2
La Jolla, California, United States, 92037
3
Los Angeles, California, United States, 90095
4
San Francisco, California, United States, 94143